Demircioglu, Fevzi
Wang, Jun http://orcid.org/0000-0003-2509-9599
Candido, Juliana
Costa, Ana S. H. http://orcid.org/0000-0001-8932-6370
Casado, Pedro http://orcid.org/0000-0002-4207-9349
de Luxan Delgado, Beatriz
Reynolds, Louise E. http://orcid.org/0000-0001-6075-1808
Gomez-Escudero, Jesus
Newport, Emma
Rajeeve, Vinothini
Baker, Ann-Marie http://orcid.org/0000-0001-8905-9137
Roy-Luzarraga, Marina
Graham, Trevor A. http://orcid.org/0000-0001-9582-1597
Foster, Julie
Wang, Yu
Campbell, James J. http://orcid.org/0000-0003-4252-5182
Singh, Rajinder
Zhang, Penglie
Schall, Thomas J.
Balkwill, Frances R.
Sosabowski, Jane
Cutillas, Pedro R. http://orcid.org/0000-0002-3426-2274
Frezza, Christian http://orcid.org/0000-0002-3293-7397
Sancho, Patricia
Hodivala-Dilke, Kairbaan
Funding for this research was provided by:
Cancer Research UK (C8218/A21453)
Worldwide Cancer Research (16-0390 2016)
Article History
Received: 23 October 2019
Accepted: 18 February 2020
First Online: 10 March 2020
Competing interests
: The authors have no competing interests except Y.W., J.J.C., R.S., P.Z. and T.J.S. who are all employees of ChemoCentryx and developed and provided the CCr1i/CCR2i double inhibitor for the study.